Status:
RECRUITING
The Outcome of Chronic Kidney Disease Patients With Obstructive Sleep Apnea Syndrome
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Chronic Kidney Diseases
OSAS (Obstructive Sleep Apneas Syndrome)
Eligibility:
All Genders
18-75 years
Brief Summary
Obstructive sleep apnea (OSA) is highly prevalent in chronic kidney disease (CKD) patients and strongly linked to obesity, metabolic syndrome, and type 2 diabetes. Besides elevating cardiovascular dis...
Eligibility Criteria
Inclusion
- Voluntarily sign the informed consent form;
- Aged ≥ 18 years and \< 75 years;
- Patients with CKD stages 3-4, with an eGFR of 15-60 ml/min/1.73m² calculated using the CKD-EPI formula for at least 3 months.
Exclusion
- Patients receiving oxygen therapy or continuous positive airway pressure (CPAP) treatment;
- Patients with other sleep disorders, including restless legs syndrome, periodic limb movement disorder, etc.;
- Patients with other severe comorbidities: Severe heart failure (NYHA class III or IV); Myocardial infarction, unstable angina, or stroke within the past 3 months; Severe arrhythmias requiring medication or device therapy; Respiratory diseases, including COPD, asthma, thoracic deformities, etc.; Neurological disorders, including myasthenia gravis, Parkinson's disease, Alzheimer's disease, etc.; Active liver disease or severe hepatic insufficiency; Psychiatric conditions, including depression, anxiety disorders, etc.; History of malignancy within the past 5 years (except cured basal cell carcinoma); Uncontrolled hyperthyroidism;
- Patients who underwent surgery or had acute infections within the past 3 months;
- Current heavy alcohol consumption:Females: \>3 drinks/day or \>7 drinks/week; Males: \>4 drinks/day or \>14 drinks/week (1 standard drink = 14g of alcohol)
- Current use of medications that may severely interfere with sleep, such as antipsychotics, antiepileptics, antiparkinsonian drugs, antidepressants, opioids, etc.;
- Females who are pregnant or lactating at screening or baseline;
- Inability to comply with the study due to: Low education level, language barriers, inability to tolerate or complete sleep monitoring, or other reasons preventing completion of study procedures (e.g., follow-up);
- Deemed unsuitable for participation by the investigator's judgment.
Key Trial Info
Start Date :
July 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2029
Estimated Enrollment :
356 Patients enrolled
Trial Details
Trial ID
NCT06971874
Start Date
July 17 2025
End Date
December 31 2029
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China, 518000